Effect of add-on direct renin inhibitor aliskiren in patients with non-diabetes related chronic kidney disease

BMC Nephrology

Wen-Sheng Liu³  Chih-Yu Yang²  Chih-Ching Lin²  Der-Cherng Tarng⁴  Wu-Chang Yang²  Yung-Tai Chen⁵  Szu-yuan Li¹ 

[1] Institute of Clinical of Medicine, National Yang-Ming University, Taipei, Taiwan;School of Medicine, National Yang-Ming University, Taipei, Taiwan;Division of Nephrology, Department of Medicine, Taipei City Hospital, Zhong-Xing Branch, Taipei, Taiwan;Department and Institute of Physiology, National Yang-Ming University, Taipei, Taiwan;Department of Medicine, Taipei City Hospital Heping Fuyou Branch, Taipei, Taiwan

关键词: CKD;    Proteinuria;    Direct renin inhibitor;    Aliskiren;   

Others  :  1083122
DOI  :  10.1186/1471-2369-13-89

 received in 2012-02-02, accepted in 2012-07-12,  发布年份 2012

【 摘 要 】

Background

The renin-angiotensin-aldosterone system (RAAS) plays an important role in the progression of chronic kidney disease (CKD). Although dual RAAS inhibition results in worse renal outcomes than monotherapy in high risk type 2 diabetes patients, the effect of dual RAAS inhibition in patients with non-DM CKD is unclear. The aim of this study was to evaluate the potential renoprotective effect of add-on direct renin inhibitor in non-DM CKD patients.

Methods

We retrospectively enrolled 189 non-DM CKD patients who had been taking angiotensin II receptor blockers (ARBs) for more than six months. Patients were divided into an add-on aliskiren group and an ARB monotherapy group. The primary outcomes were a decline in glomerular filtration rate (GFR) and a reduction in urinary protein-to-creatinine ratio at six months.

Results

The baseline characteristics of the two groups were similar. Aliskiren 150 mg daily reduced the urinary protein-to-creatinine ratio by 26% (95% confidence interval, 15 to 37%; p < 0.001). The decline in GFR was smaller in the add-on aliskiren group (−2.1 vs. -4.0 ml/min, p = 0.038). Add-on aliskiren had a neutral effect on serum potassium in the non-DM CKD patients. In subgroup analysis, the proteinuria-reducing effect of aliskiren was more prominent in patients with a GFR less than 60 ml/min, and in patients with a urinary protein-to-creatinine ratio greater than 1.8. The effect of aliskiren in retarding the decline in GFR was more prominent in patients with hypertensive nephropathy than in those with glomerulonephritis.

Conclusion

Add-on direct renin inhibitor aliskiren (150 mg daily) safely reduced proteinuria and attenuated the decline in GFR in the non-DM CKD patients who were receiving ARBs.

【 授权许可】

   
2012 Chen et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Schroten NF, Gaillard CA, van Veldhuisen DJ, Szymanski MK, Hillege HL, de Boer RA: New roles for renin and prorenin in heart failure and cardiorenal crosstalk. Heart Fail Rev 2012, 17(2):191-201.
• [2]Remuzzi G, Perico N, Macia M, Ruggenenti P: The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. Kidney Int Suppl 2005, 99:S57-S65.
• [3]Remuzzi G, Bertani T: Pathophysiology of progressive nephropathies. N Engl J Med 1998, 339(20):1448-1456.
• [4]Taft JL, Nolan CJ, Yeung SP, Hewitson TD, Martin FI: Clinical and histological correlations of decline in renal function in diabetic patients with proteinuria. Diabetes 1994, 43(8):1046-1051.
• [5]Ziyadeh FN, Goldfarb S: The renal tubulointerstitium in diabetes mellitus. Kidney Int 1991, 39(3):464-475.
• [6]The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia): Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997, 349(9069):1857-1863.
• [7]Titan SM, M. Vieira J J, Dominguez WV, Barros RT, Zatz R: ACEI and ARB combination therapy in patients with macroalbuminuric diabetic nephropathy and low socioeconomic level: a double-blind randomized clinical trial. Clinical nephrology 2011, 76(4):273-83.
• [8]Hull S, Dreyer G, Badrick E, Chesser A, Yaqoob MM: The relationship of ethnicity to the prevalence and management of hypertension and associated chronic kidney disease. BMC Nephrology 2011, 12:41. BioMed Central Full Text
• [9]Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, Ponticelli C, Ritz E, Zucchelli P: Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 1996, 334(15):939-945.
• [10]Hou FF, Zhang X, Zhang GH, Xie D, Chen PY, Zhang WR, Jiang JP, Liang M, Wang GB, Liu ZR, et al.: Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med 2006, 354(2):131-140.
• [11]Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P: Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. Ugeskr Laeger 2001, 163(40):5519-5524.
• [12]Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C: Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008, 358(15):1547-1559.
• [13]Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Ghadanfar M, Weissbach N, Xiang Z, et al.: Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association 2009, 24(5):1663-1671.
• [14]Gross O, Girgert R, Rubel D, Temme J, Theissen S, Muller GA: Renal protective effects of aliskiren beyond its antihypertensive property in a mouse model of progressive fibrosis. Am J Hypertens 2011, 24(3):355-361.
• [15]Bakris GL, Siomos M, Richardson D, Janssen I, Bolton WK, Hebert L, Agarwal R, Catanzaro D: ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group. Kidney Int 2000, 58(5):2084-2092.
• [16]Adler SG, Feld S, Striker L, Striker G, LaPage J, Esposito C, Aboulhosn J, Barba L, Cha DR, Nast CC: Glomerular type IV collagen in patients with diabetic nephropathy with and without additional glomerular disease. Kidney Int 2000, 57(5):2084-2092.
• [17]Sun CY, Cherng WJ, Jian HZ, Hsu HH, Wu IW: Hsu HJ. Wu MS: Aliskiren reduced renal fibrosis in mice with chronic ischemic kidney injury-beyond the direct renin inhibition. Hypertens Res; 2011.
• [18]Chen N, Hsu CC, Yamagata K, Langham R: Challenging chronic kidney disease: experience from chronic kidney disease prevention programs in Shanghai, Japan, Taiwan and Australia. Nephrology (Carlton) 2010, 15(Suppl 2):31-36.
• [19]Wei SY, Chang YY, Mau LW, Lin MY, Chiu HC, Tsai JC, Huang CJ, Chen HC, Hwang SJ: Chronic kidney disease care program improves quality of pre-end-stage renal disease care and reduces medical costs. Nephrology (Carlton) 2010, 15(1):108-115.
• [20]Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999, 130(6):461-470.
• [21]Ruggenenti P, Perna A, Gherardi G, Garini G, Zoccali C, Salvadori M, Scolari F, Schena FP, Remuzzi G: Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 1999, 354(9176):359-364.
• [22]Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345(12):851-860.
• [23]Porter AM: Ramipril in non-diabetic renal failure (REIN study) Ramipril Efficiency in Nephropathy Study. Lancet 1997, 350(9079):736. author reply 736–737
• [24]Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK: Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008, 358(23):2433-2446.
• [25]Persson F, Lewis JB, Lewis EJ, Rossing P, Hollenberg NK, Parving HH: Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy. Diabetes Care 2010, 33(11):2304-2309.
• [26]Tang SC, Leung JC, Lai KN: The kallikrein-kinin system. Contrib Nephrol 2011, 170:145-155.
• [27]Wu WP, Chang CH, Chiu YT, Ku CL, Wen MC, Shu KH, Wu MJ: A reduction of unilateral ureteral obstruction-induced renal fibrosis by a therapy combining valsartan with aliskiren. Am J Physiol Renal Physiol 2010, 299(5):F929-F941.
• [28]Choi DE, Jeong JY, Lim BJ, Chang YK, Na KR, Shin YT, Lee KW: Aliskiren ameliorates renal inflammation and fibrosis induced by unilateral ureteral obstruction in mice. JUrol 2011, 186(2):694-701.
• [29]Weir MR, Bush C, Anderson DR, Zhang J, Keefe D, Satlin A: Antihypertensive efficacy, safety, and tolerability of the oral direct renin inhibitor aliskiren in patients with hypertension: a pooled analysis. J Am SocHypertens 2007, 1(4):264-277.
• [30]López V, Martin M, Cobelo C, Aranda P, Cabello M, Sola E, Gutierrez C, Burgos D, Martínez D, Hernandez D: Renin-angiotensin system dual blockade using angiotensin receptor plus aliskiren decreases severe proteinuria in kidney transplant recipients. Transplant Proc 2010, 42(8):2883-2885.
• [31]Tang SC, Lin M, Tam S, Au WS, Ma MK, Yap DY, Ho YW, Lai KN: Aliskiren combined with losartan in immunoglobulin A nephropathy: an open-labeled pilot study. Nephrol Dial Transplant 2012, 27(2):613-618.
• [32]Nakamura T, Sato E, Amaha M, Kawagoe Y, Maeda S, Yamagishi SI: Addition of aliskiren to olmesartan ameliorates tubular injury in chronic kidney disease patients partly by reducing proteinuria. J Renin Angiotensin Aldosterone Syst 2011.